Mutations in TET2 (leading to decreased 5-hydroxymethylcytosine levels) have been associated with various hematologic malignancies [33], although the exact mechanism of how TET2 contributes to the development of such cancers remains unclear [34]. The gene discussed is TET2; the disease is cancer.